This study carried out statistics and analysis on the immune function and prognosis of early-stage breast cancer patients with low HER-2 expression undergoing different chemotherapy combination and compared the differences in clinical efficacy, adverse reactions, and immune function of patients before and after chemotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.